This cross-talk suggests that therapies tested in sepsis (like IL-1 blockers, metabolic cofactor supplementation) could be repurposed in high-risk surgical patients
But are GLP-1 receptor agonists already being challenged by this next wave of incretin therapy
Foundayo appears to be the latest advancement toward convenience and flexibility in the GLP-1 agonist space
doi:10.1113/jphysiol.2012.244897 Paddon-Jones D, Sheffield-Moore M, Katsanos CS, et al
Description: L-Carnitine is thought to be like a shuttle, bringing fuel into heart cells to be burned as energy
The clinical applications of IGF-1 LR3 span across various growth deficiencies and conditions requiring anabolic support, including hormone deficiencies leading to short stature, Turner Syndrome, muscle-wasting diseases, and conditions associated with pituitary tumors